- Home
- RMAX vs SGHT Comparison
RMAX vs SGHT Comparison
Compare RMAX & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- SGHT
- Stock Information
- Founded
- RMAX 1973
- SGHT 2011
- Country
- RMAX United States
- SGHT United States
- Employees
- RMAX N/A
- SGHT N/A
- Industry
- RMAX Real Estate
- SGHT Medical Specialities
- Sector
- RMAX Finance
- SGHT Health Care
- Exchange
- RMAX Nasdaq
- SGHT Nasdaq
- Market Cap
- RMAX 187.5M
- SGHT 193.2M
- IPO Year
- RMAX 2013
- SGHT 2021
- Fundamental
- Price
- RMAX $7.93
- SGHT $5.06
- Analyst Decision
- RMAX Hold
- SGHT Buy
- Analyst Count
- RMAX 1
- SGHT 8
- Target Price
- RMAX $9.00
- SGHT $4.50
- AVG Volume (30 Days)
- RMAX 150.4K
- SGHT 214.4K
- Earning Date
- RMAX 10-30-2025
- SGHT 11-06-2025
- Dividend Yield
- RMAX N/A
- SGHT N/A
- EPS Growth
- RMAX N/A
- SGHT N/A
- EPS
- RMAX 0.62
- SGHT N/A
- Revenue
- RMAX $292,931,000.00
- SGHT $76,303,000.00
- Revenue This Year
- RMAX N/A
- SGHT N/A
- Revenue Next Year
- RMAX N/A
- SGHT $12.04
- P/E Ratio
- RMAX $12.82
- SGHT N/A
- Revenue Growth
- RMAX N/A
- SGHT N/A
- 52 Week Low
- RMAX $6.90
- SGHT $2.03
- 52 Week High
- RMAX $14.31
- SGHT $5.33
- Technical
- Relative Strength Index (RSI)
- RMAX 33.21
- SGHT 69.79
- Support Level
- RMAX $8.18
- SGHT $4.92
- Resistance Level
- RMAX $8.68
- SGHT $5.25
- Average True Range (ATR)
- RMAX 0.26
- SGHT 0.34
- MACD
- RMAX -0.02
- SGHT 0.08
- Stochastic Oscillator
- RMAX 29.32
- SGHT 87.68
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.